

JC10 Rec'd PCT/PTO 28 OCT 2005

FORM PTO-1390 (Modified)
U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE
(REV 12-2004)

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		ATTORNEY'S DOCKET NUMBER 065691-0413 U.S. APPLICATION NO. (if known, see 37 C.F.R. 1.61) 107555060 Unassigned
INTERNATIONAL APPLICATION NO. PCT/IB2004/001874	INTERNATIONAL FILING DATE 04/28/2004	PRIORITY DATE CLAIMED 04/28/2003
TITLE OF INVENTION USE OF TYROSINE KINASE INHIBITORS FOR TREATING CEREBRAL ISCHEMIA		
APPLICANT(S) FOR DO/EO/US Jean-Pierre KINET et al.		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
<p>1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.</p> <p>2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.</p> <p>3. <input type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.</p> <p>4. <input type="checkbox"/> The US has been elected (Article 31).</p> <p>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) <ul style="list-style-type: none"> <input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau). <input checked="" type="checkbox"/> has been communicated by the International Bureau. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US) </p> <p>6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). <ul style="list-style-type: none"> <input type="checkbox"/> is attached hereto. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4). </p> <p>7. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) <ul style="list-style-type: none"> <input type="checkbox"/> are attached hereto (required only if not transmitted by the International Bureau). <input type="checkbox"/> have been communicated by the International Bureau. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. <input type="checkbox"/> have not been made and will not be made. </p> <p>8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</p> <p>9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).</p> <p>10. <input type="checkbox"/> An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</p>		
Items 11 to 20 below concern other document(s) or information included:		
<p>11. <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</p> <p>12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</p> <p>13. <input checked="" type="checkbox"/> A Preliminary Amendment.</p> <p>14. <input checked="" type="checkbox"/> An Application Data Sheet under 37 CFR 1.76.</p> <p>15. <input type="checkbox"/> A substitute specification.</p> <p>16. <input type="checkbox"/> A power of attorney and/or change of address letter.</p> <p>17. <input checked="" type="checkbox"/> A Transmittal of Nucleotide Sequence And/Or Amino Acid Sequence Disclosures; Statement to Support Filing and Submission in Accordance with 37 C.F.R. §1.821-§1.825; Paper Copy of Sequence Listing and computer-readable Form (CRF) Diskette.</p> <p>18. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4).</p> <p>19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).</p> <p>20. <input checked="" type="checkbox"/> Other items or information: Copy of International Search Report (2 pages).</p>		

FORM PTO-1390 (Modified)

WASH_1489125.1

JC06 Rec'd PCT/PTO 28 OCT 2005

U.S. APPLICATION NO. (If known, see 37 CFR. 1.5) Unassigned 10/555060	INTERNATIONAL APPLICATION NO. PCT/IB2004/001874	ATTORNEY'S DOCKET NUMBER 065691-0413	
The following fees have been submitted:			
21. <input checked="" type="checkbox"/> Basic national fee \$300 22. <input checked="" type="checkbox"/> Examination fee \$100 If International preliminary examination report prepared by USPTO and all claims satisfy provisions of PCT Article 33(1)-(4) \$200 All other situations \$200			
23. <input checked="" type="checkbox"/> Search fee Search fee (37 CFR 1.445(a)(2)) has been paid on the international application to the USPTO as an International Searching Authority \$100 International Search Report prepared and provided to the Office \$400 All other situations \$500			
TOTAL OF ABOVE 21, 22 and 23 = \$ 1000.00			
<input checked="" type="checkbox"/> Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$ for each additional 50 sheets of paper or fraction thereof.			
Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof (round up to a whole number)	
117 - 100 =	17 /50 =	1	
x \$250.00 \$ 250.00			
Surcharge of \$130.00 for furnishing the oath or declaration later than 30 months from the earliest claimed priority date (37 CFR 1.492(e)) \$ 0.00			
CLAIMS		NUMBER FILED	
Total Claims		3 - 20 =	0
Independent Claims		1 - 3 =	0
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$ 360.00
TOTAL OF ABOVE CALCULATIONS =			\$ 1250.00
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. Fees above are reduced by ½.			\$ 625.00
SUBTOTAL =			\$ 625.00
Processing fee of 130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(i)) \$ 0.00			
TOTAL NATIONAL FEE =			\$ 625.00
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). 40.00 per property			\$ 0.00
TOTAL FEES ENCLOSED =			\$ 625.00
			Amount to be refunded:
			charged:
a. <input checked="" type="checkbox"/> A check in the amount of <u>\$625.00</u> to cover the above fees is enclosed. b. <input type="checkbox"/> Please charge my Deposit Account No. <u>19-0741</u> in the amount of _____ to cover the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>19-0741</u> . A duplicate copy of this sheet is enclosed. d. <input type="checkbox"/> Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038. NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status.			
SEND ALL CORRESPONDENCE TO:			
Foley & Lardner LLP Customer Number: 22428		 SIGNATURE <u>Stephen B. Maebius</u> NAME <u>35,264</u> REGISTRATION NUMBER	

10/555060
JCOS Rec'd PCT/PTO 28 OCT 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
ATTORNEY DOCKET NO. 065691-0413

Applicant: Jean-Pierre KINET et al.

Title: USE OF TYROSINE KINASE INHIBITORS FOR TREATING
CEREBRAL ISCHEMIA

Appl. No.: Unassigned

Filing Date: 10/28/2005

Examiner: Unassigned

Art Unit: Unassigned

**TRANSMITTAL OF NUCLEOTIDE SEQUENCE
AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Commissioner for Patents
PO Box 1450
Alexandria, Virginia 22313-1450

Sir:

Enclosed are copies of the Sequence Listing and Statement to Support Filing and Submission in accordance with 37 C.F.R. § 1.821-§1.825. Also enclosed is a diskette containing the Sequence Listing in computer readable form.

Please direct all correspondence to the undersigned attorney or agent at the address indicated below.

Respectfully submitted,

October 28, 2005

Date

FOLEY & LARDNER LLP
Customer Number: 22428
Telephone: (202) 672-5569
Facsimile: (202) 672-5399



Stephen B. Maebius
Attorney for Applicant
Registration No. 35,264